FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549
-------------	------	-------

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Orchard Therapeutics plc [ORTX]								elationship deck all applic	able)		rson(s) to Issuer			
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/14/2023								Officer below)	(give title		Other (s below)	pecify
C/O ORCHARD THERAPEUTICS PLC				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ir	6. Individual or Joint/Group Filing (Check Applicable					
245 HAMMERSMITH ROAD				_	and an arrange of a significant reconstruction of the significant re							Line	Line) X Form filed by One Reporting Person					
(Street)												Form filed by More than One Reporting Person						
LONDO	N X	0	W6 8PW			مار	10hE	1(0)	Tranca	otic	n Ind							
(City)	(S	tate)	(Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Inst						ant to a contr						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				action 2A. Deemed Execution Date if any (Month/Day/Yea		Date,	r, Transaction Dispose Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 and		Beneficia Owned F	es For ally (D) Following (I)		orm: Direct D) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D) Price		Transact	Reported Transaction(s) (Instr. 3 and 4)		[(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date curity or Exercise (Month/Day/Year) if any		ate,	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				,	Code		(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares		(Instr. 4)	ייונא)		
Stock Option (Right to Buy)	\$0.495	06/14/2023			A		105,000		(1)	06/	13/2033	Ordinary Shares ⁽²⁾	105,000	\$0.00	105,00	0	D	

Explanation of Responses:

- 1. All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company.
- 2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

Remarks:

/s/ Frank Thomas, as attorneyin-fact

06/16/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.